Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Trifluridine/Tipiracil for Recurrent, Metastatic Gastric and Gastro-oesophageal Junction Adenocarcinoma

Approval is based on results from the TAGS trial
27 Feb 2019
Gastrointestinal cancers;  Anticancer agents & Biologic therapy

On 22 February 2019, the US Food and Drug Administration (FDA) approved trifluridine/tipiracil tablets (LONSURF, Taiho Pharmaceutical Co., Ltd.)—a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor—for adult patients with metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Approval was based on TAGS (NCT02500043), an international, randomised, double-blind, placebo-controlled trial in 507 patients with metastatic gastric or GEJ adenocarcinoma previously treated with at least two prior lines of chemotherapy. Patients were randomised 2:1 to receive Lonsurf (n=337) 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle with best supportive care (BSC) or matching placebo (n=170) with BSC until disease progression or unacceptable toxicity.

Median overall survival was 5.7 months (4.8, 6.2) for patients receiving Lonsurf and 3.6 months (3.1, 4.1) for those receiving placebo (hazard ratio: 0.69; 95% CI: 0.56, 0.85; p = 0.0006). Progression-free survival was also longer in patients randomised to the Lonsurf arm (hazard ratio 0.56; 95% CI: 0.46, 0.68; p < 0.0001).

In the TAGS trial, the most common adverse reactions or laboratory abnormalities (≥10% incidence) in patients treated with Lonsurf occurring at a higher rate than in patients receiving placebo were neutropenia, anaemia, nausea, decreased appetite, thrombocytopenia, vomiting, and diarrhoea.

The recommended Lonsurf dose and schedule is 35 mg/m2/dose orally twice daily with food on days 1 through 5 and days 8 through 12 of each 28-day cycle.

Full prescribing information for LONSURF is available here.

FDA granted this application priority review and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 27 Feb 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings